Prevent

About

Early screening to prevent pre-eclampsia complications

Prevent addresses the critical issue of pre-eclampsia, a leading cause of maternal and neonatal mortality, by introducing an innovative early screening test. Unlike traditional methods, the test identifies high-risk women between 11 and 16 weeks of pregnancy, allowing for early intervention. By detecting risk early, expectant mothers can receive preventive care, such as low-dose aspirin, well before symptoms develop. This proactive approach aims to improve outcomes and reduce the overall impact of pre-eclampsia

Student

Ella Fouhy
University college of Dublin
I am a final-year PhD candidate in Biochemistry at University College Dublin, where my research centers on investigating the early circulating environment in maternal blood that precedes the diagnosis of pre-eclampsia. My work focuses on the potential of nanoparticles known as "Extracellular Vesicles," which I am exploring as novel biomarkers for disease detection and prediction. I am passionate about advancing maternal health through innovative research, and I aim to contribute to the development of more effective diagnostic tools for pregnancy-related complications. more